Year: 2025
Type: article
Abstract: Main Points• The primary result of our study is that the use of bivaluridine as a primary anticoagulant in extracorporeal membrane oxygenation (ECMO) does not cause any decrease in anticoagulant effectiveness.• In our study, evaluating the number of patients with thrombus and bleeding alongside the total amount of replaced blood products suggests that the use of bivaluridine is more suitable than the use of unfractionated heparin (UFH) in patients undergoing Veno-Venous ECMO.In the bivaluridine group, where all patients had coronavirus disease-2019 (COVID-19), no difference occurred in thrombotic events despite the prothrombotic effect of COVID-19.• The total amount of replaced erythrocyte solution and total amount of fresh frozen plasma solution was statistically significantly higher in the UFH group than in the bivalirudin group.• The cost of providing 15-day anticoagulation in the UFH group is considerably lower than in the bivalirudin group, which is an advantage for the use of UFH.
Language: English
Subfield: Biomedical Engineering
Field: Engineering
Domain: Physical Sciences
Open Access status: diamond
OpenAlex ID: W4410371015